文献速递妇产影像US

孕11-13周母体血清糖基化纤连蛋白筛查子痫前期

Screening for pre-eclampsia by maternal serum glycosylated fibronectin at 11-13 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-09-09

该病例对照研究在孕11+0至13+6周检测母体血清糖基化纤连蛋白(GlyFn),联合平均动脉压、子宫动脉搏动指数和胎盘生长因子筛查子痫前期。早产型子痫前期筛查中,母体因素联合MAP、UtA-PI和PlGF的检出率为80%、AUC为0.949,以GlyFn替代PlGF或UtA-PI效果相似;足月型子痫前期和妊娠期高血压筛查效果不佳。

要点

  • 孕11-13周母体因素联合MAP、UtA-PI和PlGF筛查早产型子痫前期,10%假阳性率下检出率80%、AUC 0.949。
  • 以GlyFn替代PlGF或UtA-PI后筛查早产型子痫前期效果相似(检出率79%-81%,AUC 0.932-0.946)。
  • 足月型子痫前期筛查效果不佳,母体因素联合MAP、UtA-PI和PlGF检出率仅39%。

核心结论

  • GlyFn可能是孕早期筛查早产型子痫前期的有用生物标志物,但该病例对照研究结果需经前瞻性筛查研究验证;孕11+0至13+6周用任何生物标志物组合筛查足月型子痫前期或妊娠期高血压效果均不佳。

研究设计与样本

  • 病例对照研究,样本来自单胎妊娠非干预筛查研究的储存样本,早产型子痫前期、足月型子痫前期、早产型妊娠期高血压、足月型妊娠期高血压各100例及1000例无妊娠并发症血压正常对照;GlyFn用即时检测设备测定,PlGF用时间分辨荧光法测定。

诊断标准与关键数值

  • 早产型子痫前期筛查:母体因素单独检出率50%、AUC 0.834;母体因素联合MAP、UtA-PI和PlGF检出率80%、AUC 0.949;母体因素联合MAP、UtA-PI和GlyFn检出率79%、AUC 0.946;母体因素联合MAP、PlGF和GlyFn检出率81%、AUC 0.932;以上均在10%固定假阳性率下。

临床应用与阅片要点

  • 早产型子痫前期筛查中可用GlyFn替代PlGF或UtA-PI,效果相似;足月型子痫前期筛查中母体因素单独检出率35%,联合MAP、UtA-PI和PlGF仅增至39%。

局限性

  • 该研究为病例对照研究,原文结论指出其发现需经前瞻性筛查研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To examine the performance of screening for preterm and term pre-eclampsia (PE) at 11-13 weeks' gestation by maternal factors and combinations of maternal serum glycosylated fibronectin (GlyFn), mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PlGF).

METHODS: This was a case-control study in which maternal serum GlyFn was measured using a point-of-care device in stored samples from a non-intervention screening study of singleton pregnancies at 11 + 0 to 13 + 6 weeks' gestation. In the same samples, PlGF was measured by time-resolved fluorometry. We used samples from women who delivered with PE at < 37 weeks' gestation (n = 100), PE at ≥ 37 weeks (n = 100), gestational hypertension (GH) at < 37 weeks (n = 100), GH at ≥ 37 weeks (n = 100) and 1000 normotensive controls with no pregnancy complications. In all cases, MAP and UtA-PI had been measured during the routine 11-13-week visit. Levels of GlyFn were transformed to multiples of the expected median (MoM) values after adjusting for maternal demographic characteristics and elements of medical history. Similarly, the measured values of MAP, UtA-PI and PlGF were converted to MoMs. The competing-risks model was used to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics, with various combinations of biomarker MoM values to derive the patient-specific risks of delivery with PE or GH at < 37 and ≥ 37 weeks' gestation. Screening performance was estimated by examining the area under the receiver-operating-characteristics curve (AUC) and detection rate (DR) at 10% fixed false-positive rate (FPR).

RESULTS: The maternal characteristics and elements of medical history with a significant effect on the measurement of GlyFn were maternal age, weight, height, race, smoking status and history of PE. In pregnancies that developed PE, GlyFn MoM was increased and the deviation from normal decreased with increasing gestational age at delivery. The DR and AUC of screening for delivery with PE at < 37 weeks' gestation by maternal factors alone were 50% and 0.834, respectively, and these increased to 80% and 0.949, respectively, when maternal risk factors were combined with MAP, UtA-PI and PlGF (triple test). The performance of the triple test was similar to that of screening by a combination of maternal factors, MAP, UtA-PI and GlyFn (DR, 79%; AUC, 0.946) and that of screening by a combination of maternal factors, MAP, PlGF and GlyFn (DR, 81%; AUC, 0.932). The performance of screening for delivery with PE at ≥ 37 weeks' gestation was poor; the DR for screening by maternal factors alone was 35% and increased to only 39% with use of the triple test. Similar results were obtained when GlyFn replaced PlGF or UtA-PI in the triple test. The DR of screening for GH with delivery at < 37 and ≥ 37 weeks' gestation by maternal factors alone was 34% and 25%, respectively, and increased to 54% and 31%, respectively, with use of the triple test. Similar results were obtained when GlyFn replaced PlGF or UtA-PI in the triple test.

CONCLUSIONS: GlyFn is a potentially useful biomarker in first-trimester screening for preterm PE, but the findings of this case-control study need to be validated by prospective screening studies. The performance of screening for term PE or GH at 11 + 0 to 13 + 6 weeks' gestation by any combination of biomarkers is poor. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sokratous, Bednorz, Sarli, et al. Screening for pre-eclampsia by maternal serum glycosylated fibronectin at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2023. PMID: 37401855. doi:10.1002/uog.26303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。